US healthcare, US news, Pharmaceuticals industry Business | The Guardian
Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medicationAn obscure federal statute is allowing US pharmacies to flood the market with unvetted knockoffs of Ozempic, the pricey weight-loss drug that is reducing and transforming the weight and silhouettes of millions of Americans.According to a Bloomberg investigation published Monday, a “blind spot” in Food and Drug Administration (FDA) regulations that allows pharmacies and compounders to reproduce drugs that are in short supply has helped to create a market of unbranded weight-loss drugs worth $1bn annually. Continue reading…
Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication
An obscure federal statute is allowing US pharmacies to flood the market with unvetted knockoffs of Ozempic, the pricey weight-loss drug that is reducing and transforming the weight and silhouettes of millions of Americans.
According to a Bloomberg investigation published Monday, a “blind spot” in Food and Drug Administration (FDA) regulations that allows pharmacies and compounders to reproduce drugs that are in short supply has helped to create a market of unbranded weight-loss drugs worth $1bn annually.
